Reply to thread

Message: [QUOTE="Da_Aisijimo_Gou, post: 3791164, member: 264"] Late Mar-early Apr, bought some of the typically very lightly traded CYDY <3 in a Roth solely used for riskier chances. Then and now, I never believed CYDY's particularly well managed, it remains in the grays and hence has virtually no institutional holders (ahead of possible move to Nasdaq). That said, CYDY's recently added more-competent pharma leaders, begun to enhance their financials, signed prospective manufacturing agreements with Samsung Biologics and Ajinomoto (FDA-clearance dependent), and CYDY's Leronlimab/Vyrologix may luck into a narrowly-scoped FDA clearance for severe-to-critical SARS-2 patients (potentially later, other uses for Covid-19 long haulers and for breast cancer, HIV, NASH, etc.). CYDY's been up and down like a trampolined-kid since March. Not being much of a trader, I intended to hold the initial shares for a year, win or lose. Then, sold enough shares to break even >6 up to >9, and added more <3 as recent as Nov. Jader's likely correct, CYDY will potentially bump up Monday, shorters will try to pound it back down as they have since March, and CYDY may rise up again up to a Wednesday conference call into Thursday, repeat ... Sometime later in January, the Leronlimab/Vyrologix Phase III trial results for severe-to-critical patients will be unblinded. Forget about investments, ideally the FDA grants EUA such that an actual effective, therapeutic treatment finally exists. Knocking on wood for our country. [/QUOTE]

Verification: First name of men's bb coach